News

During AAPA 2024, a group of session presenters provide recommendations for the next year's agenda based on trends and development.

Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.

Peterson reviews the gastric and hormonal events linked to drugs like tirzepatide, before considering whether incretin therapies will help to finally embrace obesity as the medical condition it is.

Findings were presented at DDW and highlight the feasibility of breath analysis for microbiome metabolic characterization in the digestive system.

Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.

The MyGut digital health monitoring platform proves feasible and impactful during integration into inflammatory bowel disease care.

Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.

Higher exposure dupilumab significantly improved histologic and endoscopic outcomes in children with EoE aged 1 to <12 years.

Dubinsky explains the disconnect between patients with Crohn disease and health care providers regarding the impact of and importance of addressing bowel urgency.

At week 52 of the Phase 3 EoE KIDS trial, higher exposure dupilumab significantly improved the endoscopic reference score in children with EoE.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

The matters of long-term PCOS management may heavily depend on what stage of life the patient is in—and how the disease itself has presented.

Wei Ling Lau, MD, explains the importance of medication adherence to maximize the benefits of RAASi therapy.

Wei Ling Lau, MD, explains how to enable optimal RAASi therapy while reducing hyperkalemia risk.

Michael Shlipak, MD, MPH, explains updates to the American Heart Association's cardiovascular risk equation, which now incorporates kidney function and damage through albuminuria into its components.

An AAPA 2024 poster from University of Utah shows significant disparities in which patients are missed for depression screening, despite a clinic's universal screening protocol.

Rezaie explains findings from his recent research connecting GLP-1RA use to aspiration pneumonia after endoscopy with deep sedation.

Fendrick explains how stool-based colorectal cancer screening tests can help alleviate the current colonoscopy backlog amid growing demand for the procedure.

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.

Fendrick explains the value of additional modalities for colorectal cancer screening to combat the colonoscopy backlog and help patients get screened.

A retrospective analysis in the US found bariatric surgery lowers mortality rates and shortens hospital stays in patients admitted with NAFLD.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Initial consultations by female gastroenterologists led to a significant reduction in subsequent healthcare utilization compared with male gastroenterologists.

Jared Hassler, MD, shares his personal journey with IgAN and discusses IgAN's clinical features and diagnosis, emphasizing the importance of routine screenings for early detection.

The smartphone app demonstrated higher accuracy, sensitivity, and specificity in patients with severe anemia than those with moderate anemia.

This analysis may help bring to light more specific skin cancer-related data on the underserved population of non-Hispanic Black, or NHB, patients.

Patients with IgAN receiving iptacopan achieved a 38.3% reduction in proteinuria at month 9.